Clinical trials
Solid Cancers clinical trials
Below are recruiting solid cancers clinical trials, each written for real people, not researchers. We’re tracking 901 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05024214RecruitingPhase 1/Phase 2
Test of envafolimab plus lenvatinib for advanced solid tumors
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Bengbu, AnhuiAges 18 years+ - NCT06942104RecruitingPhase 1
New imaging agent for advanced solid tumors
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT06150365RecruitingEarly Phase 1
Personalized T-cell therapy for advanced solid tumors (KSX01-TCRT)
This study tests a personalized treatment made from your own immune cells (T cells) that are re-engineered to recognize and attack your specific tumor. It is for people with advanced solid tumors that have not responded to other treatments. If you qualify, you will have a blood draw and a tumor sample collected to create your own custom T cell therapy.
BeijingAges 18–70 - NCT06561685RecruitingPhase 1
Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Santa Monica, CaliforniaAges 18 years+ - NCT05227326RecruitingPhase 1
A new drug for solid cancers that did not respond to usual care
This early-stage (Phase 1) trial tests AOH1996 in adults with solid tumors that have stopped responding to standard treatments. It’s meant to find a safe dose and see if the drug can help, especially in cancers with limited options.
Scottsdale, ArizonaAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
Birmingham, AlabamaAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT05695638Recruiting
Genetic tumor testing to find treatments for advanced cancer
This study looks at your tumor’s genetic information to help match you to targeted treatments when standard options are no longer working. You may be offered options based on results, with the goal of helping people with incurable, worsening cancer.
AalborgAges 18 years+ - NCT06206863Recruiting
Physical activity program for cancer survivors and caregivers
This trial tests a community-based physical activity program designed for people who have had cancer or care for someone who has. The goal is to see if it can help improve health and well-being for those not currently on active treatment.
Buffalo, New YorkAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT03093688RecruitingPhase 1/Phase 2
Testing an immune-cell infusion for advanced solid tumors
This trial tests whether adding special immune cells (iNKT cells and CD8+ T cells) given by IV infusion can help treat advanced cancers. It mainly looks at safety first, and also checks whether the treatment can shrink or control cancer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07458347RecruitingPhase 1
A new oral drug for KRAS-mutated advanced cancer
This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.
Los Angeles, CaliforniaAges 18 years+ - NCT05473156RecruitingPhase 1/Phase 2
Study of AP203 for advanced solid tumors that grew despite treatment
This early-phase study tests AP203 (an investigational treatment) to see if it is safe and to look for signs it can shrink or control certain advanced cancers. The study includes a dose-finding part for many solid tumors, and a second part focused on specific lung and head/neck cancers that previously received PD-1/PD-L1 therapy.
TaipeiAges 18 years+ - NCT05003895RecruitingPhase 1
CAR-T for solid tumors with high GPC3 protein
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
Bethesda, MarylandAges 18–120 - NCT06364410RecruitingPhase 1
Testing a new drug combo for stomach and other solid tumors
This trial tests a combination of two drugs, trastuzumab deruxtecan and azenosertib, for people with stomach cancer or other solid tumors that have a specific protein called HER2. It aims to see if this combination can help when other treatments have stopped working.
Houston, TexasAges 18 years+ - NCT05579275RecruitingEarly Phase 1
Study JCXH-212 to treat advanced solid tumors safely
This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.
Beijing, Beijing MunicipalityAges 18–75 - NCT06954558RecruitingPhase 1
GK01 for advanced solid tumors that are hard to treat
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
TianjinAges 18–70 - NCT07081984RecruitingPhase 1
Testing TI-0093 for advanced HPV-16 positive cancers
This study tests a new drug, TI-0093, for people with HPV‑16 positive solid tumors (like head and neck or cervical cancer) that have come back or spread after standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
ShanghaiAges 18–75 - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Duarte, CaliforniaAges 18 years+ - NCT06006273RecruitingPhase 1
Testing a new drug combo for children with returning solid tumors
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
Houston, TexasAges 1–25 - NCT04871542Recruiting
Predicting risk of immune therapy side effects
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Anchorage, AlaskaAges 18 years+ - NCT03465592RecruitingPhase 1/Phase 2
Nivolumab after mismatched bone marrow transplant for sarcoma
This trial studies nivolumab (an immune treatment) in people with sarcoma who already had a partially mismatched bone marrow transplant. It may help the new immune system recognize and attack cancer, and researchers will also watch closely for side effects like GVHD (immune reaction after transplant) and autoimmune problems.
St. Petersburg, FloridaAges 1–40
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid cancers?
- Yes. Clin2 currently lists 901 recruiting solid cancers studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid cancers trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid cancers trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.